Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VCNX

VCNX - Vaccinex Inc Stock Price, Fair Value and News

$1.21+0.05 (+4.31%)
Market Closed

5/100

VCNX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

5/100

VCNX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.08

Target 3M

$1.22

Target 6M

$1.15

VCNX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VCNX Price Action

Last 7 days

-8.3%

Last 30 days

19.8%

Last 90 days

75.4%

Trailing 12 Months

1.7%

VCNX RSI Chart

VCNX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VCNX Valuation

Market Cap

3.6M

Price/Earnings (Trailing)

-0.19

Price/Sales (Trailing)

5.92

EV/EBITDA

-0.13

Price/Free Cashflow

-0.22

VCNX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.08

Target 3M

$1.22

Target 6M

$1.15

VCNX Fundamentals

VCNX Revenue

VCNX Earnings

VCNX Profitability

Free Cashflow Yield

-455.29%

VCNX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024124.0K356.0K388.0K601.0K
2023825.0K825.0K795.0K570.0K
202200100.0K325.0K
20211.5M1.5M900.0K900.0K
2020001.1M1.0M
2019612.0K511.0K717.0K523.0K
2018248.5K407.0K565.5K724.0K
201700090.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Vaccinex Inc

VCNX
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.
 CEO
 WEBSITEvaccinex.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES38

Vaccinex Inc Frequently Asked Questions

VCNX is the stock ticker symbol of Vaccinex Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Vaccinex Inc is 3.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check VCNX's fair value in chart for subscribers.

The fair value guage provides a quick view whether VCNX is over valued or under valued. Whether Vaccinex Inc is cheap or expensive depends on the assumptions which impact Vaccinex Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCNX.

As of Wed Jan 28 2026, VCNX's PE ratio (Price to Earnings) is -0.19 and Price to Sales (PS) ratio is 5.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCNX PE ratio will change depending on the future growth rate expectations of investors.